|
To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: Interim CDC Recommendations for nirsevimab
Date: October 24, 2023
Yesterday, October 23, 2023, a health advisory regarding nirsevimab was distributed via the CDC Health Alert Network:
“Today, CDC issued a notice via the Health Alert Network (HAN) recommending that healthcare settings that are currently experiencing shortages of nirsevimab prioritize available 100mg doses to infants at the highest risk for severe RSV disease. This includes all infants aged <6 months and select groups of older babies who have certain risk factors. Recommendations for 50mg doses of nirsevimab remain unchanged at this time.
We appreciate your support in spreading awareness of this notice and in helping families understand other prevention strategies they can employ to help protect babies from severe RSV illness, including the RSV vaccine that can be given during weeks 32 to 36 of pregnancy, and everyday health and hygiene practices like handwashing and staying home when sick.”
If you have questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov.
|
